40 related articles for article (PubMed ID: 19109590)
1. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.
Friberg LE; de Greef R; Kerbusch T; Karlsson MO
Clin Pharmacol Ther; 2009 Jul; 86(1):84-91. PubMed ID: 19387434
[TBL] [Abstract][Full Text] [Related]
2. Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling.
van Esdonk MJ; Burggraaf J; Dehez M; van der Graaf PH; Stevens J
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):229-239. PubMed ID: 32248329
[TBL] [Abstract][Full Text] [Related]
3. Modeling of prolactin response following dopamine D
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226628
[TBL] [Abstract][Full Text] [Related]
4. Impact of mathematical pharmacology on practice and theory: four case studies.
Peletier LA; Gabrielsson J
J Pharmacokinet Pharmacodyn; 2018 Feb; 45(1):3-21. PubMed ID: 28884259
[TBL] [Abstract][Full Text] [Related]
5. A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds.
van Esdonk MJ; Burggraaf J; van der Graaf PH; Stevens J
J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):389-400. PubMed ID: 28497294
[TBL] [Abstract][Full Text] [Related]
6. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.
van den Brink WJ; Wong YC; Gülave B; van der Graaf PH; de Lange EC
AAPS J; 2017 Jan; 19(1):274-285. PubMed ID: 27785749
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension.
Vezina HE; Ng CM; Vazquez DM; Barks JD; Bhatt-Mehta V
Pediatr Crit Care Med; 2014 Jul; 15(6):546-53. PubMed ID: 24797719
[TBL] [Abstract][Full Text] [Related]
8. Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.
Upton RN; Mould DR
CPT Pharmacometrics Syst Pharmacol; 2014 Jan; 3(1):e88. PubMed ID: 24384783
[TBL] [Abstract][Full Text] [Related]
9. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.
de Lange EC
Fluids Barriers CNS; 2013 Feb; 10(1):12. PubMed ID: 23432852
[TBL] [Abstract][Full Text] [Related]
10. Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.
Petersson KJ; Vermeulen AM; Friberg LE
AAPS J; 2013 Apr; 15(2):533-41. PubMed ID: 23392818
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.
Stevens J; Ploeger BA; Hammarlund-Udenaes M; Osswald G; van der Graaf PH; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):463-77. PubMed ID: 22791078
[TBL] [Abstract][Full Text] [Related]
12. Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.
Pilla Reddy V; Kozielska M; Johnson M; Vermeulen A; de Greef R; Liu J; Groothuis GM; Danhof M; Proost JH
Clin Pharmacokinet; 2011 Jul; 50(7):429-50. PubMed ID: 21651312
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.
Ma G; Friberg LE; Movin-Osswald G; Karlsson MO
Br J Clin Pharmacol; 2010 Dec; 70(6):815-24. PubMed ID: 21175437
[TBL] [Abstract][Full Text] [Related]
14. Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM.
Petersson KJ; Friberg LE; Karlsson MO
J Pharmacokinet Pharmacodyn; 2010 Oct; 37(5):493-506. PubMed ID: 20878453
[TBL] [Abstract][Full Text] [Related]
15. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia.
Bartzokis G; Lu PH; Stewart SB; Oluwadara B; Lucas AJ; Pantages J; Pratt E; Sherin JE; Altshuler LL; Mintz J; Gitlin MJ; Subotnik KL; Nuechterlein KH
Schizophr Res; 2009 Sep; 113(2-3):322-31. PubMed ID: 19616412
[TBL] [Abstract][Full Text] [Related]
16. An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.
Friberg LE; Vermeulen AM; Petersson KJ; Karlsson MO
Clin Pharmacol Ther; 2009 Apr; 85(4):409-17. PubMed ID: 19109590
[TBL] [Abstract][Full Text] [Related]
17. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
[TBL] [Abstract][Full Text] [Related]
18. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Troost PW; Lahuis BE; Hermans MH; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
J Clin Psychopharmacol; 2007 Feb; 27(1):52-7. PubMed ID: 17224713
[TBL] [Abstract][Full Text] [Related]
19. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
